IRVINE, Calif. (PRWEB) October 24, 2007
"This was the 158th ReValving(TM) procedure within the scope of our post-CE Mark Expanded Evaluation registry. When combined with the results of 191 previous cases of the feasibility, safety and efficacy trials, it demonstrates that interventional cardiology treatment of structural heart disease is no longer just a hope for the future but a reality today that provides a new treatment option for high-risk and inoperable patients," said Jacques Seguin, M.D., Ph.D., Chairman, CEO and Founder of CoreValve.
Founded in 2001, privately held CoreValve--which is headquartered in Irvine, California--has developed a proprietary delivery system and tissue heart valve for percutaneous heart valve replacement. Based on a novel catheter-and-self-expanding-frame approach on a beating heart, the proprietary CoreValve ReValving(TM) System procedure is intended to avoid open-heart surgery. It can be performed in a cardiac "cath lab" just like angioplasty and stenting, which may result in less trauma to the patient and may offer substantial cost-savings to the healthcare system. For more information about CoreValve, visit the Company's Web site at http://www.corevalve.com.
(Caution: the CoreValve ReValving(TM) System will not be available in the USA for clinical trials or for sale until further notice.)